Latest news

Want to cost-effectively benefit from our GeoMx DSP platform services? It's time!

01 / 13 / 2022

Want to cost-effectively benefit from our GeoMx DSP platform services?  It's time!

To pursue our commitment to expand cutting-edge transcriptomic approaches in order to identify novel biomarkers and discover novel actionable targets, our work rely on the GeoMx-DSP technology platform (NanoStringTM) and appropriate target panels – including the Cancer Transcriptome Atlas as well as the Whole Transcriptome Atlas (1800 and 18000 genes, respectively) – an approach which is increasingly reported in scientific publications.

Spatial transcriptomics reveals key determinants of response to immune checkpoint blockade in NSCLC

11 / 22 / 2021

Spatial transcriptomics reveals key determinants of response to immune checkpoint blockade in NSCLC

The development of immune checkpoint blockers (ICB) has considerably changed the therapeutic armamentarium for the management of cancer. Blocking the PD-1/PD-L1 axis interaction has demonstrated remarkable anti-cancer activity and has led to approval of anti-PD-1/PD-L1 drugs in several solid tumors. However, most patients receiving PD(L)-1 blockers do not derive clinical benefit. Therefore, there is a crucial need to decipher mechanisms underlying sensitivity / resistance to cancer immunotherapies which can ultimately lead to the identification of novel therapeutic targets.

Next In Vitro Shuttle Session - DC differentiation and MLR assays for immunotherapeutics screening

11 / 10 / 2021

Next In Vitro Shuttle Session - DC differentiation and MLR assays for immunotherapeutics screening

Take advantage of our upcoming shuttle session - scheduled early-December - to cost-effectively run your candidates on our robust DC differentiation and Mixed Leukocyte Reaction (MLR) assays thereby saving up to 25% on initial cost. 

Characterized through adenosine-mediated suppression results, our validated DC-based assays represent valuable tools for assessing adenosine pathway modulators as well as innovative candidate immunotherapeutics for their potential to enhance DC-mediated T cell stimulation

Spotlight on adenosine-mediated suppression of dendritic cell function

10 / 22 / 2021

Spotlight on adenosine-mediated suppression of dendritic cell function

Differentiation and maturation of competent dendritic cells (DCs) is critically dependent on their microenvironment. Among factors which can, in cancer, reach high levels in the tumor microenvironment, adenosine - one of the major immunosuppressive pathways - is known to modulate the function of many cell subsets, including DCs. Adenosine receptor stimulation skews DC differentiation toward a distinct cell population which has, unlike normal myeloid DCs, tolerogenic and suppressive phenotype expressing high levels of proinflammatory and immune suppressor factors, as well as impaired allostimulatory capacity.

A syngeneic Lewis LLC1 mouse model for preclinical immuno-oncology testing of novel anti-cancer strategies

10 / 07 / 2021

A syngeneic Lewis LLC1 mouse model for preclinical immuno-oncology testing of novel anti-cancer strategies

Fully set up and characterized syngeneic Lewis LLC1 mouse model featured by (i) a moderate tumor immune infiltration – predominantly constituted of suppressive MDSCs and (ii) accumulation of circulating MDSCs. Interestingly, we showed here that, while LLC1 tumors remain insensitive to PD1 blockade, cyclophosphamide, a reference alkylating anti-cancer agent, led to a tumor growth inhibition and survival rate improvement.

Spotlight on Explicyte integrated histology platform in Nature Cancer!

09 / 22 / 2021

Spotlight on Explicyte integrated histology platform in Nature Cancer!

In a recent collaborative work (1) supervised by Pr A. Italiano and published in Nature Cancer (2), we highlighted that the presence of mature tertiary lymphoid structures (mTLS) – a structure of prominent B cell follicles and follicular dendritic cells adjoined to a CD4/CD8 T cell-containing zone - is a new predictive biomarker for response for immune checkpoint blockers.